IL154306A0 - Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof - Google Patents

Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof

Info

Publication number
IL154306A0
IL154306A0 IL15430603A IL15430603A IL154306A0 IL 154306 A0 IL154306 A0 IL 154306A0 IL 15430603 A IL15430603 A IL 15430603A IL 15430603 A IL15430603 A IL 15430603A IL 154306 A0 IL154306 A0 IL 154306A0
Authority
IL
Israel
Prior art keywords
thieno
pharmaceutical compositions
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
IL15430603A
Other languages
English (en)
Original Assignee
Rimonyx Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rimonyx Pharmaceuticals Ltd filed Critical Rimonyx Pharmaceuticals Ltd
Priority to IL15430603A priority Critical patent/IL154306A0/xx
Publication of IL154306A0 publication Critical patent/IL154306A0/xx
Priority to JP2006502633A priority patent/JP2006516610A/ja
Priority to AU2004210241A priority patent/AU2004210241A1/en
Priority to KR1020057014345A priority patent/KR20050100655A/ko
Priority to CNA2004800093693A priority patent/CN1771037A/zh
Priority to EP04708427A priority patent/EP1589970A4/en
Priority to PCT/IL2004/000121 priority patent/WO2004069149A2/en
Priority to MXPA05008397A priority patent/MXPA05008397A/es
Priority to CA002515102A priority patent/CA2515102A1/en
Priority to US10/543,065 priority patent/US7365080B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
IL15430603A 2003-02-05 2003-02-05 Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof IL154306A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL15430603A IL154306A0 (en) 2003-02-05 2003-02-05 Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
JP2006502633A JP2006516610A (ja) 2003-02-05 2004-02-05 チエノ［２，３−ｃ］ピリジン誘導体を含む薬剤組成物、及びその使用
AU2004210241A AU2004210241A1 (en) 2003-02-05 2004-02-05 Pharmaceutical compositions comprising thieno[2,3-C]pyridine derivatives and use thereof
KR1020057014345A KR20050100655A (ko) 2003-02-05 2004-02-05 티에노〔2,3-ｃ〕피리딘 유도체를 함유하는 약제학적조성물 및 그의 용도
CNA2004800093693A CN1771037A (zh) 2003-02-05 2004-02-05 包含噻吩并[2,3－c]吡啶衍生物的药用组合物及其用途
EP04708427A EP1589970A4 (en) 2003-02-05 2004-02-05 PHARMACEUTICAL COMPOSITIONS WITH THIENO.-2,3-C-PYRIDINE DERIVATIVES AND THEIR USE
PCT/IL2004/000121 WO2004069149A2 (en) 2003-02-05 2004-02-05 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
MXPA05008397A MXPA05008397A (es) 2003-02-05 2004-02-05 Composiciones farmaceuticas que comprenden derivados de tieno[2,3-c]piridina y uso de las mismas.
CA002515102A CA2515102A1 (en) 2003-02-05 2004-02-05 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
US10/543,065 US7365080B2 (en) 2003-02-05 2004-02-05 Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15430603A IL154306A0 (en) 2003-02-05 2003-02-05 Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof

Publications (1)

Publication Number Publication Date
IL154306A0 true IL154306A0 (en) 2003-09-17

Family

ID=30011984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15430603A IL154306A0 (en) 2003-02-05 2003-02-05 Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof

Country Status (10)

Country Link
US (1) US7365080B2 (enExample)
EP (1) EP1589970A4 (enExample)
JP (1) JP2006516610A (enExample)
KR (1) KR20050100655A (enExample)
CN (1) CN1771037A (enExample)
AU (1) AU2004210241A1 (enExample)
CA (1) CA2515102A1 (enExample)
IL (1) IL154306A0 (enExample)
MX (1) MXPA05008397A (enExample)
WO (1) WO2004069149A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275214A1 (en) * 2003-12-30 2006-12-07 Rimonyx Pharmaceuticals Ltd. Methods of screening for anti-inflammatory drugs and use thereof
WO2005089068A2 (en) * 2004-03-24 2005-09-29 Rimonyx Pharmaceuticals Ltd. Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
EP1753512B1 (en) 2004-05-28 2008-07-09 Nycomed GmbH Tetrahydropyridothiophenes
DE602005007220D1 (de) 2004-06-04 2008-07-10 Nycomed Gmbh Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
JP2008501768A (ja) * 2004-06-11 2008-01-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の化合物及びテトラヒドロピリドチオフェンの使用
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
CA2596202A1 (en) 2005-02-09 2006-08-17 Altana Pharma Ag Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer
JP2008530053A (ja) 2005-02-11 2008-08-07 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
AU2006251167A1 (en) 2005-05-25 2006-11-30 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A1 (en) 2005-05-25 2006-11-30 4Sc Ag Tetrahydropyridothiophenes for use in the treatment of cancer
US20100298370A1 (en) * 2006-03-20 2010-11-25 Paul Gregor Benzothiazolyl thienopyridine derivatives and uses thereof
US8466149B2 (en) 2007-08-15 2013-06-18 Merck Sharp & Dohme Corp. 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2307440A4 (en) * 2008-07-01 2012-12-19 Zacharon Pharmaceuticals Inc HEPARAN SULFATE INHIBITORS
ES2761295T3 (es) 2009-03-02 2020-05-19 Stemsynergy Therapeutics Inc Métodos y composiciones para su uso en el tratamiento del cáncer y para reducir los efectos mediados por Wnt en una célula
MX2012012421A (es) 2010-04-28 2012-12-17 Astellas Pharma Inc Compuestos tetrahidrobenzotiofena.
WO2012148889A1 (en) * 2011-04-28 2012-11-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human apurinic/apyrimidinic endonuclease 1
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201402609RA (en) * 2011-11-29 2014-06-27 Gilead Pharmasset Llc Compositions and methods for treating hepatitis c virus
CN104829629B (zh) * 2015-03-26 2017-03-15 天津药物研究院有限公司 含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
WO2016197078A1 (en) * 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
US10106290B2 (en) 2015-12-14 2018-10-23 Westrock Shared Services, Llc Carton, blank, and method of folding
US10647725B2 (en) * 2016-04-21 2020-05-12 The University Of Toledo Anti-infective 2-aminothiophenes
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR20190098204A (ko) 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
CA3049856C (en) * 2017-01-13 2021-10-26 Tobishi Pharmaceutical Co., Ltd. Neutrophil activation regulator
WO2021050994A1 (en) * 2019-09-13 2021-03-18 Aerie Pharmaceuticals, Inc. Heterobicyclic carboxamides and uses thereof
AU2022341967A1 (en) * 2021-09-07 2024-05-16 Gismo Therapeutics, Inc. Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interactions with glycosaminoglycans, methods of treatment, and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4231299A (en) * 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
US6232320B1 (en) * 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
HK1045306A1 (zh) * 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
JP4548882B2 (ja) * 1999-11-30 2010-09-22 興和創薬株式会社 ４，５，６，７−テトラヒドロチエノ〔２，３−ｃ〕ピリジン化合物

Also Published As

Publication number Publication date
EP1589970A2 (en) 2005-11-02
KR20050100655A (ko) 2005-10-19
US7365080B2 (en) 2008-04-29
MXPA05008397A (es) 2006-02-17
US20060135529A1 (en) 2006-06-22
EP1589970A4 (en) 2008-05-21
CN1771037A (zh) 2006-05-10
WO2004069149A2 (en) 2004-08-19
AU2004210241A1 (en) 2004-08-19
WO2004069149A3 (en) 2004-11-25
JP2006516610A (ja) 2006-07-06
CA2515102A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
EP1589970A4 (en) PHARMACEUTICAL COMPOSITIONS WITH THIENO.-2,3-C-PYRIDINE DERIVATIVES AND THEIR USE
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
IL172994A0 (en) Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing them, and use
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
IL210823A0 (en) [1,2,4] TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
IL171170A (en) History of itensinoids and their pharmaceutical preparations, methods of preparation and use thereof
HUP0302997A3 (en) Phenylalanine derivatives with alpha4-integrin effect, pharmaceutical compositions containing them and their use
HUP0400784A3 (en) Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them
HUP0301722A3 (en) Pyrimidine derivatives, pharmaceutical compositions containing them and their use
IL178294A0 (en) Thienopyridine derivatives and pharmaceutical compositions containing the same
HUP0402018A3 (en) 5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL161623A (en) Nicotin-or isonicotin benzothiazole derivatives, their preparation and pharmaceutical compositions comprising them
IL173195A0 (en) Cyclovinylazoline derivatives, their preparation and pharmaceutical compositions containing them
HUP0500024A3 (en) 6-aminomorphinane derivatives, their use and pharmaceutical compositions containing them
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
PL375373A1 (en) Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
HUP0401588A3 (en) Indeno[1,2-c]pyrazol-4-one derivatives useful as anti-cancer and anti-proliferative agents and pharmaceutical compositions containing them
HUP0204354A3 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same and their use
IL166821A0 (en) Novel 1,4-diazabicycloalkane derivatives their preparation and use
AU2003251695A1 (en) Novel thiophene derivatives, preparation method thereof and pharmaceutical compositions containing same
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them